P. vera "Science"
- 2001.12.xx – Cancer Mail from the National Cancer Institute
- 2006.03.07 – Fourth Generation P. vera
- 2006.04.07 – Mutation In Blood Stem Cells
- 2006.11.06 – POLYCYTHEMIA PROTOCOL: THE INVESTIGATION OF POLYCYTHEMIA VERA INCIDENCE IN THE TAMAQUA AREA OF PENNSYLVANIA
- 2006.11.XX – ON THE TRAIL OF A POINT MUTATION THE DISCOVERY OF A BLOOD-CANCER GENE RAISES TANTALIZING QUESTIONS
- 2006.12.10 – GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER [ABSTRACT #5]
- 2007.04.21 – Options limited for blood illness (PV)
- 2007.08.24 – POINTING THE ATSDR IN THE RIGHT DIRECTION
- 2007.10.12 – Incyte’s Novel JAK Inhibitor, INCB18424
- 2007.11.12 – JAK2-V617F or JAK2 exon 12 mutations
- 2007.11.16 – ATSDR PV Abstract
- 2007.11.20 – First Quantitative JAK2 V617F Mutation Kit
- 2007.11.23 – Merck_Manual
- 2007.12.05 – Top Scientists to Receive Prestigious Awards
- 2007.12.06 – Initiation of Clinical Trial of JAK2 Inhibitor
- 2007.12.07 – Researcher Discovers What Fuels Certain Cancer Mutation
- 2007.12.10 – A Novel Selective Inhibitor of JAK2
- 2007.12.10 – OHSU Cancer Institute researcher discovers what fuels certain cancer mutation
- 2007.12.11 – Understanding Chronic Myeloid Leukemia
- 2007.12.12 – New Cancer Discovery, Hormone to Blame
- 2007.12.12 – Phase I data for myelofibrosis drug
- 2008.01.08 – Incyte to Report Positive Clinical Results from JAK Inhibitor
- 2008.01.08 – Results of Polycythemia Vera Investigation
- 2008.01.14 – Dr. Mehta-A new blood test-Do we know JAK?
- 2008.01.22 – JAK2V617F mutation screening in WHO 2008 criteria
- 2008.02.29 – myeloproliferative disease support group
- 2008.03.07 – New Genetic Test Detects PV
- 2008.03.17 – JAK2 Clinical Candidate
- 2008.04.07 – Drug Targets Three Kinds of Leukemia
- 2008.04.07 – New Therapy for Rare Blood Disorder
- 2008.04.07 – Treatment reverses blood disorder in mice, study finds
- 2008.04.15 – Drug Successfully Treats Chronic Blood Cancer In Mice
- 2008.08.xx – Weird- Cancer Cluster in Northeastern PA
- 2008.09.21 – Genetic Link Between Leukemia And Down’s Syndrome
- 2008.09.22 – Too much iron brings increased health risks
- 2008.10.26 – JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement
- 2008.10.30 – link between coal combustion waste, rare cancer cluster
- 2008.12.08 – Competitor Analysis for Janus Kinase (JAK) Inhibitors
- 2008.12.09 – Promising new drug blocks mutation in bone marrow cancers
- 2008.7.20 – JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)
- 2009.01.06 – The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis
- 2009.01.08 – PV_ therapy-resistant cancers
- 2009.01.30 – Treatment of Hematological Malignancies
- 2009.03.05 – Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
- 2009.03.05 – TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
- 2009.03.15 – germline JAK2 SNP is associated with
- 2009.03.17 – Are waste-coal power plants making us sick?
- 2009.03.xx – Federal Agency Fails to Protect People
- 2009.05.04 – JAK2 Molecular Diagnostic Assays
- 2009.05.14 – Father Sues Utility
- 2009.05.22 – Is there a cancer cluster in Love Canal
- 2009.05.27 – Astex reports positive data from its Phase I study
- 2009.05.27 – Recombinant Human Erythropoietin Injection
- 2009.05.28 – A Common Genetic Mechanism in Malignant Bone Marrow Diseases
- 2009.05.28 – Candidate Tumor Suppressor Gene Implicated in Myeloid Cancers
- 2009.05.28 – Incyte Provides Update on Special Protocol Assessment for INCB18424
- 2009.05.28 – Mutation in TET2 in Myeloid Cancers
- 2009.05.28 – Search_Results_NEJM_JAK2
- 2009.05.29 – FDA, Clinical Trial Updates- JNJ, INCY, MEDX, CYTX, AGN, PPHM
- 2009.05.29 – Clinical and hematological presentation of children and adolescents with polycythemia vera
- 2009.05.29 – JAK2V617F-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis
- 2009.05.29 – TET2 defects present early in myeloid cancers
- 2009.05.29 -Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
- 2009.05.31 – Acquired mutations in TET2 are common in myelodysplastic syndromes.
- 2009.06.01 – Incyte Provides Update On Special Protocol Assessment For INCB18424 As A New Treatment For Myelofibrosis
- 2009.06.04 – Gene and microRNA analysis of neutrophils from patients with polycythemia vera
- 2009.06.07 – An Insight On Incyte Corp
- 2009.06.08 – Mutation in TET2 in Myeloid Cancers
- 2009.06.14 – Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms
- 2009.06.18 – Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
- 2009.06.19 – Cephalon Cancer Drug Shows No Increase In Survival Rate
- 2009.06.19 – Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
- 2009.06.22 – Cytopia Lodges IND for JAK2 Inhibitor CYT387
- 2009.06.29 – Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms
- 2009.07.02 – Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- 2009.07.04 – Acquired mutations in TET2 are common in myelodysplastic syndromes
- 2009.07.21 – Assessment for INCB18424
- 2009.07.24 – JAK2 V617F mutation in myeloid neoplasms with 3q21 and 3q26 abnormalities in Chinese patients
- 2009.07.24 – JAK2 V617F mutation is associated with 5q- syndrome in Chinese
- 2009.07.28 – New drug for children with high-risk leukemia
- 2009.07.29 – New drug may help treat childhood leukemia
- 2009.07.29 – Sheba’s Dr. Shai Izraeli discovers novel alternative to chemotherapy for children with leukemia
- 2009.07.30 – Incyte Provides Update on Drug Development Programs
- 2009.07.31 -MYELOPROLIFERATIVE DISORDERS – BIOLOGY AND MANAGEMENT
- 2009.08.01 – Drug Alternative Childhood Leukemia Chemo Developed
- 2009.08.05 – Onyx Pharmaceuticals – ONX 0803 selective JAK2 inhibitor
- 2009.08.07 – TET2 mutations in myelodysplasia and myeloid malignancies
- 2009.08.10 – Incyte Presents Investors with Unique Dilemmas
- 2009.08.11 – Chronic Myelomonocytic Leukemia with der(9)t(1;9)(q11;q34) as a Sole Abnormality
- 2009.08.11 – New drug hope for children with leukemia
- 2009.08.13 – TET2 Mutation Is an Independent Favorable Prognostic Factor in Myelodysplastic Syndromes (MDS)
- 2009.08.14 – Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells.
- 2009.08.16 – Discovery of genetic link to blood cancers
- 2009.08.20 – Gene Mutation Predicts Outcome In Blood Disorder
- 2009.08.20 – Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
- 2009.08.22 – Pomalidomide Active for Treatment of Anemia of Myelofibrosis
- 2009.08.25 – JAK2 inhibitor CYT387
- 2009.08.25 – urbaneangel – POLYCYTHEMIA VERA
- 2009.08.31 – Genetic Link Between Leukemia And Down’s Syndrome
- 2009.09.01 – Loss-of-Function TET2 Mutations- Adding Fire to Hematologic Malignancies?
- 2009.09.03 – Cytopia’s CYT387 Receives FDA Clearance to Start US Clinical Trials
- 2009.09.03 – TargeGen Announces Initiation Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myeloproliferative Disease Patients
- 2009.09.04 – The Activation of the JAK2/STAT5 Pathway Is Commonly Involved in Signaling through the Human IL-5 Receptor
- 2009.09.10 -Mutation in TET2 in Myeloid Cancers
- 2009.09.10 -Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
- 2009.09.11 -Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes
- 2009.09.19 – A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
- 2009.09.19 – How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis
- 2009.09.21 – Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis
- 2009.09.22 – Incyte says psoriasis drug meets main goal, shares up
- 2009.09.23 – How do JAK2-inhibitors work in myelofibrosis- An alternative hypothesis
- 2009.09.23 – JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)
- 2009.09.27 – JAK2 phosphorylates histone H3Y41 and excludes HP1 from chromatin
- 2009.09.27 – Scientists find broken ‘switch’ link to leukemia
- 2009.09.28 – New hope in fight against blood cancer
- 2009.09.28 – Scientists discover new route to leukaemia
- 2009.09.28 – Scientists uncover ‘genetic switch’ that can trigger leukaemia
- 2009.09.30 – A broken genetic “switch” has been discovered that can trigger leukaemia.
- 2009.09.30 – Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
- 2009.10.01 – In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients- a new disease paradigm
- 2009.10.01 – Regulation of JAK2 by miR-135a- prognostic impact in classic Hodgkin lymphoma
- 2009.10.02 – Cancer Research UK scientists identify a nuclear role for JAK2 in the phosphorylation of H3Y41
- 2009.10.06 – YM BioSciences inks deal to acquire Cytopia
- 2009.10.08 – JAK2 phosphorylates histone H3Y41 and excludes HP1 from chromatin
- 2009.10.08 – JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
- 2009.10.09 – Cytopia achieves grant of further patent for JAK2 program
- 2009.10.14 – Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells.
- 2009.10.18 – New Chromosomal Abnormality Identified in Leukemia Associated with Down Syndrome
- 2009.10.22 – TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients